Cooperative Agreement U01CA313321
Award Date 6/24/26
Completion Date 5/31/31
Dollars Obligated $681K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10032, USA
Similar Awards
- Cooperative Agreement Summary The National Cancer Institute awarded a $556,865 Cooperative Agreement to Trustees of Tufts College under the Cancer Biology Research program (CFDA 93.396) on September 1, 2025, with a completion date of August 31, 2030. This five-year research initiative investigates stiffness-mediated genetic selection of cells, examining how mechanical properties of substrates select for cellular variants adapted to growth on soft or stiff environments. The research extends...
- Federal Cooperative Agreement Summary The University of North Carolina at Chapel Hill received a $1.28 million Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through July 31, 2030. This award supports fundamental research into the molecular mechanisms underlying metastasis organ tropism—specifically, why certain breast cancer subtypes preferentially metastasize to specific sites (e.g.,...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $1.45 million Cooperative Agreement to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Biology Research program (CFDA 93.396) on August 11, 2025, with completion targeted for May 31, 2027. The award funds research and development of engineered probiotic bacteria, specifically E. coli Nissle 1917 (ECN), designed to identify precancerous colorectal lesions and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Cooperative Agreement Summary The University of Southern California received a $531,693 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on August 4, 2025, with a completion date of July 31, 2030. This award supports research to develop a validated computational model of the tumor-immune ecosystem in breast cancer. The project will deliver an agent-based computational model that captures tumor-immune...
- Federal Cooperative Agreement Summary Harvard Medical School, through its Office of Research Administration (UEI: JDLVAVGYJQ21), received a $1.22 million Cooperative Agreement from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, with completion targeted for September 26, 2025. The award funds research to systematically establish optimal tumor handling protocols for Ramp Up Dynamic BH3 Profiling (RUDBP), a functional precision...
- Award Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $1.92M to The Leland Stanford Junior University for fundamental research under the Cancer Biology Research program (CFDA 93.396). Commencing July 25, 2025, and extending through May 31, 2030, this award funds a systems-level investigation into pancreatic ductal adenocarcinoma (PDAC) metastasis, specifically addressing the molecular determinants governing metastatic ability, organ tropism, and immune...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $155,052 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on December 25, 2025, with completion targeted for June 30, 2028. This award supports biomedical research training and workforce development in cancer research aligned with the National Cancer Program. The grant funds research conducted at Columbia University's Health Sciences Division...
- This Cooperative Agreement award from the National Cancer Institute, a division of the Department of Health and Human Services, provides $380,509 under the Cancer Biology Research program to The Trustees of Columbia University in New York. The award supports research to elucidate the molecular drivers of melanoma liver metastasis and associated resistance to immunotherapies. Specifically, the researchers will characterize a novel preclinical mouse model that recapitulates genomic and...
- Cooperative Agreement Award Summary Cornell University received a $413,509 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 4, 2025, through July 31, 2028. The award funds development of a deep learning-based 3D network biology knowledge portal to advance precision oncology. The primary deliverable is the PIONEER (Protein-Protein Interaction Interface Prediction) pipeline, a big-data-driven deep...